Cancer News and Research

Latest Cancer News and Research

NT-proBNP guided heart failure care associated with reduced cardiovascular events

Roche and study investigators from Harvard University and Massachusetts General Hospital announced today that in the PROTECT (Pro-BNP Outpatient Tailored Chronic HF Therapy) trial, a strategy of NT-proBNP guided heart failure care was independently associated with a significant reduction in total cardiovascular events, the primary composite endpoint of the study, which included worsening heart failure, heart failure hospitalization and cardiovascular related death

From Roche Sequencing and Life Science 17 Nov 2010

New slice-tilting instrument for in-vitro research on brain tissue

The nanoelectronics research centre imec and Peira, a Belgium-based manufacturer of pharmaceutical and chemical research instruments, jointly developed an innovative slice-tilting instrument for in-vitro research on brain tissue. The new tool enables long-term studying of brain cultures through electronic stimulation and read-out, essential in getting insight into the functioning of the brain.

17 Nov 2010

Risk of radiation-induced breast cancer from mammographic screening slight in comparison to benefits

The risk of radiation-induced breast cancer from mammography screening is slight in comparison to the benefit of expected lives saved, according to a new study appearing online and in the January issue of the journal Radiology.

17 Nov 2010

Study finds phenotypic plasticity among melanoma cells

University of Michigan researchers have determined that most types of melanoma cells can form malignant tumors, providing new evidence that the deadliest form of skin cancer does not conform to the increasingly popular cancer stem cell model.

17 Nov 2010

New method to improve coordinating care in children with chronic conditions

Children with chronic health conditions such as cystic fibrosis, type 1 diabetes, sickle cell diseases and cerebral palsy represent less than two percent of the population but can consume more than 50 percent of resources at children's hospitals throughout the country. Coordinating care for these children has historically been difficult because hospitals have varying methods to identify them in their systems.

17 Nov 2010

University of Oslo opens new Centre for Molecular Medicine Norway

The University of Oslo recently opened its new Centre for Molecular Medicine Norway (NCMM). The centre is the second in Norway to form a partnership with the European Molecular Biology Laboratory (EMBL).

17 Nov 2010

Targeted therapies could treat a broad range of cancers: Research

Targeted cancer therapies such as trastuzumab (Herceptin), gefitinib (Iressa) and erlotinib (Tarceva) could be used to treat a wider range of cancers than previously thought, according to new research presented today (Wednesday) at the 22nd EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Berlin.

17 Nov 2010

MedImmune to present data on oncology portfolio at two medical congresses in Europe and the U.S.

Today, MedImmune announced that researchers will present data from its oncology portfolio, including new clinical data, at two upcoming medical congresses in Europe and the United States.

17 Nov 2010

China Medical second quarter revenue increases 21.5% to RMB201.8 million

China Medical Technologies, Inc., a leading China-based advanced in-vitro diagnostic company, today announced its unaudited financial results for the second fiscal quarter ended September 30, 2010

17 Nov 2010

Infinity announces enrollment in IPI-926 Phase 1b/2 clinical trial for pancreatic cancer

Infinity Pharmaceuticals, Inc. today announced that enrollment is ongoing locally for a Phase 1b/2 clinical trial of IPI-926, Infinity's oral molecule that inhibits Smoothened, a key component of the Hedgehog pathway, in combination with Gemzar (gemcitabine) in patients with previously untreated, metastatic pancreatic cancer.

17 Nov 2010

Scientists uncover minute mechanism of nuclear pore complexes at molecular level

Dr. Joseph Glavy at Stevens Institute of Technology studies the smallest and most basic elements of life. The Assistant Professor of Chemical Biology runs the Glavy Lab, where advanced student scientists study the nuclear pore complexes (NPCs) in cells, observing the minutest mechanisms of life as they unfold during mitosis. The Glavy Lab's formal purpose is to study the NPC at the molecular level in the pursuit of the unknown or unexpected in the well-studied but not always well-understood nuclei of living cells.

17 Nov 2010

Garvan Institute professor receives 2010 Prime Minister's Prize for Science

Professor John Shine AO FAA, Executive Director of Sydney's Garvan Institute of Medical Research, received the 2010 Prime Minister's Prize for Science, the nation's most highly respected award for scientific achievement, in Parliament House tonight.

17 Nov 2010

Never-smokers have better chance of surviving head and neck cancer

Patients with head and neck cancer who have never smoked have much better survival rates after radiation therapy than patients with a history of smoking, new research from UC Davis Cancer Center has found.

17 Nov 2010

Mirna to present data on miRNA Replacement Therapies for cancer at CPRIT Conference

Mirna Therapeutics, Inc., a leading developer of microRNA (miRNA)-based therapeutics, announced today that it will present new data at the inaugural CPRIT Innovations in Cancer Prevention and Research Conference, November 17-19, 2010 in Austin, TX.

17 Nov 2010

Dartmouth Atlas Project releases new report on cancer care

A new report released today from the Dartmouth Atlas Project showing that individuals in some areas of the country are far less likely to receive comfort care in accordance with their wishes has drawn the attention of the nation's hospice and palliative care community.

17 Nov 2010

Pharmigene receives patent for methods to detect genetic alleles in SJS and TENS

Pharmigene, a leader in advancing personalized medicine and reducing severe adverse reactions to drugs through genetic-based diagnostic solutions, announced it has been granted patents in the United States, Europe, Australia, Singapore and Taiwan. The patents cover methods to detect the presence of key genetic alleles in individual patients being considered for treatment with drugs that have been linked to the development of adverse drug reactions including Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

17 Nov 2010

EMA approves CTI's Pixuvri Pediatric Investigation Plan for lymphoid malignancies and solid tumors

Cell Therapeutics, Inc. ("CTI") announced today that the European Medicines Agency ("EMA") approved CTI's Pixuvri (pixantrone dimaleate) Pediatric Investigation Plan ("PIP") for the treatment of lymphoid malignancies and solid tumors in children between the ages of six months and 18 years. Previously, the Pediatric Committee (the "PDCO") of the EMA adopted an opinion agreeing to the PIP and a deferral of the initiation of the clinical studies until after the drug receives EMA approval.

17 Nov 2010

USPTO issues patent to Neogenix’s 16C3 monoclonal antibody for colorectal, pancreatic cancer

Neogenix Oncology, Inc. announced today that the U.S. Patent and Trademark Office (USPTO) has issued patent number 7,829,678 B2, with claims relating to 16C3 antibody, the company's monoclonal antibody for colorectal and pancreatic cancer.

17 Nov 2010

Predictive Biosciences, Epigenomics extend GSTP1 licensing agreement for prostate cancer

Epigenomics AG , the cancer diagnostics company, and Predictive Biosciences, a commercial stage, fully-integrated developer of novel molecular diagnostic cancer assays and a provider of anatomic pathology laboratory products and services, today announced that they have extended their licensing agreement for the prostate cancer biomarker GSTP1, originally signed in April 2009.

17 Nov 2010

CDH Proton Center commences treatment with IBA's Proteus 235 proton delivery system

IBA (Ion Beam Applications S.A.) and ProCure Treatment Centers, Inc., (ProCure) announced today that the CDH Proton Center, A ProCure Center, located outside Chicago, recently delivered proton radiation treatment to its first patients using IBA's Proteus 235 proton delivery system. It took only 24 months to build the facility, install the equipment and treat the first patient, setting a new world record in bringing this important technology to patients who could benefit.

17 Nov 2010

Cancer News and Research

Latest Cancer News and Research

NT-proBNP guided heart failure care associated with reduced cardiovascular events

New slice-tilting instrument for in-vitro research on brain tissue

Risk of radiation-induced breast cancer from mammographic screening slight in comparison to benefits

Study finds phenotypic plasticity among melanoma cells

New method to improve coordinating care in children with chronic conditions

University of Oslo opens new Centre for Molecular Medicine Norway

Targeted therapies could treat a broad range of cancers: Research

MedImmune to present data on oncology portfolio at two medical congresses in Europe and the U.S.

China Medical second quarter revenue increases 21.5% to RMB201.8 million

Infinity announces enrollment in IPI-926 Phase 1b/2 clinical trial for pancreatic cancer

Scientists uncover minute mechanism of nuclear pore complexes at molecular level

Garvan Institute professor receives 2010 Prime Minister's Prize for Science

Never-smokers have better chance of surviving head and neck cancer

Mirna to present data on miRNA Replacement Therapies for cancer at CPRIT Conference

Dartmouth Atlas Project releases new report on cancer care

Pharmigene receives patent for methods to detect genetic alleles in SJS and TENS

EMA approves CTI's Pixuvri Pediatric Investigation Plan for lymphoid malignancies and solid tumors

USPTO issues patent to Neogenix’s 16C3 monoclonal antibody for colorectal, pancreatic cancer

Predictive Biosciences, Epigenomics extend GSTP1 licensing agreement for prostate cancer

CDH Proton Center commences treatment with IBA's Proteus 235 proton delivery system

Industry Focus: Cell & Gene Therapy eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Cancer News and Research

Latest Cancer News and Research

Industry Focus: Cell & Gene Therapy eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in